Uses of Daztavir 123

Daztavir 123 medicine contains the main ingredient is Tenofovir disoproxil (as Tenofovir disoproxil fumarate 150mg). This is an active ingredient that possesses a helical single-nucleotide diester structure similar to adenosine monophosphate. Mechanism of action of Tenofovir disoproxil fumarate undergoes diester hydrolysis to convert to tenofovir. Subsequently, phosphorylation occurs by cellular enzymes to form tenofovir diphosphate. From here, tenofovir diphosphate inhibits HIV-1 reverse transcriptase activity by competing with the natural substrate deoxyadenosine-5' triphosphate and, after binding to DNA, induces DNA chain termination.

Use of Daztavir 123 in combination with other antiretroviral agents (not used alone) in the treatment of HIV - type 1 (HIV-1) infection in adult patients.
Use of Daztavir in combination with other antiretroviral agents in the prevention of HIV infection after exposure to the disease (occupational or non-occupational causes) in individuals at risk of viral infection.
Use of Daztavir 123 in the treatment of chronic hepatitis B in adults.
However, do not use Daztavir 123 in patients with hypersensitivity to any of the ingredients.

Daztavir is a drug used orally with reference doses as follows:
Patients with HIV: Take the drug at a dose of 1 tablet x 1 time / day, in combination with other antiretroviral drugs. Use in the prevention of HIV infection after occupational exposure: Need to take the drug within a few hours and continue for the next 4 weeks if tolerated with a dose of 1 tablet x 1 time / day, combined with antiretroviral drugs (Including lamivudine or emtricitabine). Use in the prevention of non-occupational HIV infection: Need to take the drug within 72 hours and continue for 28 days with a dose of 1 tablet x 1 time / day. Attention patients need to combine at least 2 other antiretroviral drugs. Chronic hepatitis B: Use with a dose of 1 tablet x 1 time / day for more than 48 weeks. Special cases: Patients with renal impairment with creatinine clearance ≥ 50ml/min can receive the usual dose once daily. For patients with creatinine clearance 30 - 49 ml/min and administered every 48 hours. In the case of patients with creatinine clearance 10 - 29 ml/min, use every 72 - 96 hours. Hemodialysis patients: Use with a dose of 7 days or 12 hours after dialysis.

The use of Daztavir may cause some of the following side effects:
Mild effects on the gastrointestinal tract, especially diarrhea, vomiting and nausea, abdominal pain, flatulence, dyspepsia, increased feeling of boredom eat. Daztavir may cause elevated serum amylase levels and pancreatitis. Hypophosphataemia and skin rash are also common. Increased liver enzymes, increased blood triglyceride levels, hyperglycemia and neutropenia. Causes peripheral neuropathy, headache, dizziness, insomnia, depression, weakness, profuse sweating and muscle pain. Renal failure, acute renal failure or having Fanconi syndrome. Lactic acidosis, often accompanied by severe hepatomegaly and steatosis, is common during treatment with Daztavir in combination with nucleoside reverse transcriptase inhibitors. Patients pay attention to notify the doctor when side effects appear for timely support.

Drugs that affect or are normally eliminated by the kidneys: Daztavir may interact with drugs that decrease renal function or compete for renal tubular secretion including acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir. Co-administration will result in increased plasma concentrations of tenofovir or co-administered drugs. HIV protease inhibitors: Co-administration with Daztavir will create synergistic or synergistic interactions between Daztavir and HIV protease inhibitors such as amprenavir, atazanavir, indinavir, ritonavir, saquinavir. Non-nucleoside reverse transcriptase inhibitors: There is a potential for additive or synergistic interactions between Daztavir and non-nucleoside reverse transcriptase inhibitors including delavirdine, efavirenz, and nevirapine. Nucleoside reverse transcriptase inhibitors: There is a potential for additive or synergistic interactions between Daztavir and nucleoside reverse transcriptase inhibitors such as abacavir, didanosine, stavudine, zalcitabine, emtricitabine, lamivudine, zidovudine. Oral contraceptives : Be careful when co-administering with ethinyl estradiol and norgestimate containing drugs.

Daztavir 123 may affect the redistribution or accumulation of body fat, including central obesity, anterior and posterior neck hypertrophy as well as damage to the peripheral nerves, face, mammary gland enlargement. In particular, the same person can develop cushing's syndrome when taking antiretroviral drugs.
Use of Daztavir 123 together with lamivudine and efavirenz-containing drugs in HIV-infected patients is associated with a risk of decreased lumbar spine mineral density, increased levels of 4 biochemical factors in bone metabolism, especially increased serum parathyroid hormone levels. Therefore, patients with a history of fractures, or at risk of osteoporosis should closely monitor their bones.
When using Daztavir 123 in women of reproductive age should be accompanied by effective methods of contraception.
With some information shared above, you have had the best overview of Daztavir 123. The use of the drug must be followed by the doctor's prescription to ensure the best possible effect for the user.